On Tuesday, Y-Mabs Therapeutics Inc (NASDAQ: YMAB) opened higher 3.45% from the last session, before settling in for the closing price of $5.80. Price fluctuations for YMAB have ranged from $5.71 to $20.90 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 46.29%. Company’s average yearly earnings per share was noted -28.70% at the time writing. With a float of $36.97 million, this company’s outstanding shares have now reached $44.77 million.
Considering the fact that the conglomerate employs 100 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 88.83%, operating margin of -33.66%, and the pretax margin is -27.28%.
Y-Mabs Therapeutics Inc (YMAB) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Y-Mabs Therapeutics Inc is 17.46%, while institutional ownership is 60.22%. The most recent insider transaction that took place on Sep 13 ’24, was worth 875,550. In this transaction CHIEF BUSINESS OFFICER of this company sold 65,000 shares at a rate of $13.47, taking the stock ownership to the 97,681 shares. Before that another transaction happened on Sep 16 ’24, when Company’s CHIEF BUSINESS OFFICER sold 30,000 for $12.97, making the entire transaction worth $389,100. This insider now owns 67,681 shares in total.
Y-Mabs Therapeutics Inc (YMAB) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -28.70% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -12.81% during the next five years compared to 20.06% growth over the previous five years of trading.
Y-Mabs Therapeutics Inc (NASDAQ: YMAB) Trading Performance Indicators
Check out the current performance indicators for Y-Mabs Therapeutics Inc (YMAB). In the past quarter, the stock posted a quick ratio of 3.54. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.18.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.54, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.58 in one year’s time.
Technical Analysis of Y-Mabs Therapeutics Inc (YMAB)
Compared to the last year’s volume of 0.43 million, its volume of 0.42 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 12.74%. Additionally, its Average True Range was 0.46.
During the past 100 days, Y-Mabs Therapeutics Inc’s (YMAB) raw stochastic average was set at 2.79%, which indicates a significant decrease from 25.45% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 30.06% in the past 14 days, which was lower than the 57.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.34, while its 200-day Moving Average is $11.98. Nevertheless, the first resistance level for the watch stands at $6.13 in the near term. At $6.26, the stock is likely to face the second major resistance level. The third major resistance level sits at $6.45. If the price goes on to break the first support level at $5.81, it is likely to go to the next support level at $5.62. Should the price break the second support level, the third support level stands at $5.49.
Y-Mabs Therapeutics Inc (NASDAQ: YMAB) Key Stats
There are currently 44,789K shares outstanding in the company with a market cap of 268.73 million. Presently, the company’s annual sales total 84,820 K according to its annual income of -21,430 K. Last quarter, the company’s sales amounted to 18,460 K and its income totaled -7,000 K.
